Secondary impairment of pancreatic function as a cause of severe malabsorption in intestinal giardiasis: a case report.
We report the case of a 54-year-old male patient hospitalized for diarrhea and weight loss (8 kg over the previous three months). At admission, we observed pale oral and conjunctival mucosa and peripheral edema of the lower limbs. Stool frequency was 8-10 per day. Laboratory data were as follows: hemoglobin, 11 g/dL; total proteins, 4.3 g/dL; albumin, 2 g/dL; pseudocholinesterase, 1248 U/L; triglycerides, 54 mg/dL; serum cholesterol, 102 mg/dL; calcium, 7.9 mg/dL. Fecal fat was 8.2 g/24 hr. Fecal chymotrypsin (FCT) was 2.3 U/g. A duodenal probe was performed after administration of intravenous secretin and cerulein stimulation, and a contemporaneous mucosal biopsy was taken at the ligament of Treitz. Microscopic examination showed numerous Giardia lamblia in the fluid collected. Pancreatic enzyme activity in the duodenal fluid showed a severe reduction in lipase: 120 U/ml/min (normal value = 600 U/ml/min). Small bowel bacterial overgrowth was excluded by microbiologic examination of intestinal fluid. The patient was treated with metronidazole, leading to a complete remission of symptoms. Immediately after stopping treatment, the FCT was 15.2 U/g. Four months after hospitalization, the patient's weight had increased by 11 kg and he was asymptomatic; total proteins were 6.7 g/dL; albumin, 3.8 g/dL; triglycerides, 104 mg/dL; cholesterol, 152 mg/dL; pseudocholinesterase, 3,567 mg/dL; calcium, 10 mg/dL; steatorrhea was 3.6 g/24 hr and fecal chymotrypsin was 88 U/g. This case describes a severe, reversible impairment in pancreatic function leading to clinical malabsorption in the presence of Giardia infection.
Carroccio
A
A
Cattedra di Medicina Interna, Universita di Palermo, Italy.
Montalto
G
G
Iacono
G
G
Ippolito
S
S
Soresi
M
M
Notarbartolo
A
A
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D000994:Antitrichomonal Agents; D010188:Exocrine Pancreatic Insufficiency / Q000209:etiology*; D016829:Giardia lamblia / Q000302:isolation & purification; D005873:Giardiasis / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008286:Malabsorption Syndromes / Q000209:etiology*; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged
D000981:Antiprotozoal Agents; D000994:Antitrichomonal Agents; D008795:Metronidazole